Hans Wildiers

机构：KU Leuven

发表论文 76 篇 · 总被引 1962 次 · h-index 13

代表论文

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 166)
• Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (2024 · Journal of Clinical Oncology · 被引 107)
• A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry (2023 · Breast Cancer Research · 被引 13)
• Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). (2025 · Journal of Clinical Oncology · 被引 12)
• Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review (2024 · Breast Cancer Research · 被引 10)
• Clinical challenges and proposed solutions for patients with invasive lobular breast cancer (2025 · Annals of Oncology · 被引 8)